Boehringer Ingelheim, founded in 1885 and family-owned ever since, is working on breakthrough therapies that transform lives, now and in generations to come. As a leading research-driven biopharmaceutical company, Boehringer Ingelheim creates value through innovation in areas of high unmet medical need.
Among other disease areas, Boehringer Ingelheim is concentrating research efforts and investment in cardio–renal–metabolic (CRM) diseases – a group of interconnected conditions affecting the heart, kidneys, and the metabolic system. More than 1 billion people worldwide are living with CRM diseases such as obesity, type 2 diabetes, chronic kidney disease, liver disease, heart failure, and cardiovascular disease. Despite significant improvements in life expectancy over the last decades, CRM diseases are still amongst the leading causes of death globally – and their prevalence is expected to continue to rise.
Due to the interconnectivity of the CRM systems, people are often impacted by multiple health conditions, posing an increased physical and emotional burden. Boehringer Ingelheim is addressing these challenges by taking a holistic approach to the management of CRM conditions. While the onset of one disease can increase the risk of developing another, improvement in one disease can have additional benefits in others. Considering this, Boehringer Ingelheim is exploring synergies between disease mechanisms and pathways to deliver the next wave of innovative therapies aiming to restore the balance between the interconnected CRM systems, reducing the risk of serious complications, thereby improving the outcomes of people living with CRM diseases.
Our legacy in cardio–renal–metabolic diseases
Boehringer Ingelheim’s significant expertise and leadership in CRM diseases is evidenced by our track record of excellence in research and landmark clinical trials, which have resulted in important achievements in recent years, especially in thromboembolic diseases, type 2 diabetes, heart failure, and chronic kidney disease. Boehringer Ingelheim developed the first pharmacotherapy for type 2 diabetes that demonstrated substantial cardiovascular benefits in a cardiovascular outcomes trial. This has paved the way for a shift towards a holistic view on CRM diseases, including heart failure and chronic kidney disease. By building on our long-standing legacy and deep knowledge, Boehringer Ingelheim is developing a portfolio of novel compounds that address CRM conditions with enduring high unmet medical need. One prominent CRM condition that is being researched is obesity, a metabolic and multifactorial disease at the center of CRM diseases.
Currax Pharmaceuticals LLC is a specialty biopharmaceutical company focused on enhancing the lives of patients worldwide by expanding access to life-changing medications that treat diseases such as obesity. Currax distributes a range of both branded and generic pharmaceutical products. For more information, please visit our website: www.curraxpharma.com
HSE Health and Wellbeing shapes and translates key health and wellbeing national policies into actions and supports implementation so that people live healthier lives and the burden of chronic disease on individuals, the health service and society as a whole is reduced. Key areas of focus for us are obesity, tobacco, alcohol, physical activity, diet, mental health and sexual health. We provide evidence informed training and resources for health professionals as well as behaviour change tools and programmes for individuals and communities. To learn more about what we do why not check out our HSE Talking about Health podcast wherever you get your podcasts or on YouTube; follow us on Twitter @HSEhealthW or join our mailing list at health&wellbeing.strategy@hse.ie
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit https://www.lilly.ie/
VIVUS is a biopharmaceutical company committed to advancing innovative clinical therapies. With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. We are a focused organization with the expertise and insights to advance innovative new therapies. VIVUS manufactures Qsymia® (phentermine and topiramate extended-release) CIV and PANCREAZE® (pancrelipase) delayed-release capsules.
Our headquarters, Phoenix Pharmaceuticals, Inc. specializes in complex peptide research. For over forty years, we have grown knowledge and expertise in the fields of antibodies, ELISA kits, RIA kits, I-125 labeled products, peptide libraries, and magnetic beads with a focus on obesity. Our catalogue has thousands of items and even offers custom peptide synthesis and antibody production. If your research is in peptides, Phoenix Europe GmbH is a wonderful resource.
Some of our latest product developments include optimized Irisin kits, new Gelsolin peptides and MRAP2 related products, which add to our extensive catalog of products for obesity, diabetes, and cardiovascular areas of focus. Researchers worldwide trust the quality, reliability, and experience of working with Phoenix's team of talented biochemists and researchers.
You are very welcome to visit our frequently updated website:
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed to transform the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases by rapidly advancing care and precision medicines addressing the root cause. Our science is dedicated to the understanding of hyperphagia and severe obesity caused by genetic variants leading to an impaired MC4R pathway. For more information about the science and our solutions, please visit our website: www.path4hcps.com
We are a medium-sized company which develops and markets high-quality pharmaceutical products. As manufacturer of medical devices with a wide expertise, we are strongly set close to Frankfurt/Main, Germany and count with a distribution network in more than 60 countries, both EU and EFTA.
Corporate strengths such as high quality standards, continuous innovation and the commitment of our employees constitute the basis for our leadership position in the dietetic segment in German pharmacy trade.
Certmedica has core competences in developing and marketing high quality standard medical devices throughout Europe. Additionally to the medical devices standards, we observe the GMP and GCP guidelines as they are applied by the pharmaceutical industry. Certmedica’s quality system conforms to the highest standards in the pharmaceutical industry.
COMPANY PROFILE
COSMED, an Italian company established in 1980, designs, manufactures, and sells worldwide diagnostic medical devices to assess Cardiopulmonary and Metabolic functions and Body Composition, addressing the needs of Health Care and Research public and private organizations and professionals operating in the Hospital, Primary Care, Sport Science and Human Performance, and Health and Wellness markets.
COSMED medical devices are grouped into five Product Lines:
COSMED employs worldwide more than 200 people, with over 20 mechanical, electronic and software engineers engaged in R&D. Its headquarters are in Rome (Italy) and it has two plants located in Italy and USA.
Direct operations, through its fully owned subsidiaries, are held in Australia, Denmark, France, Germany, Hong Kong, Netherland, Switzerland, and USA, and with over 80 Business Partners, are covered more than 100 countries.
Accuracy, reliability and duration of diagnostic medical devices and the innovative software platform OMNIA, worldwide superior customer care, first class technical support, effective training services, along with regular software updates and guaranteed availability of original spare parts and supply of consumables, guarantee COSMED customers to preserve and exploit their investments over time.
PronoKal Health Group, S.L.
Roger de Lluria, 58
08009 Barcelona –Spain-
Contact: Ivan Benavent
W: www.pronokal.com
P: +34 931 833 300 / +34 687 160 069
E: ivan.b@pronokal.com
PronoKal Group is a multinational company based in Spain, and a pioneer and leader in science, nutrition and technology for weight loss, which develops individual treatments supervised by healthcare professionals.
The company's core mission is to help people reach a healthy weight with a view to improving their health and the pathologies associated with overweight and obesity. With these solutions, the company works to increase people's well-being and quality of life, helping them to acquire healthy habits.
PronoKal Group began its activities in 2004 with the launch of the PronoKal® Method in Spain. Since 2009, the expansion and internationalisation has been consolidated: PronoKal Group is currently in 12 countries. More recently, in 2022, the company was integrated into the Nestlé Health Science division.
PronoKal Group is a leader in research and the top publisher of articles on the benefits of nutritional ketosis for health, with more than 35 studies published in prestigious international scientific journals. The organisation is currently working with a new line of research related to genetics.
The success of our medical treatment is backed by more than 700,000 patients treated and more than 8,000 doctors who trust in the rigour and effectiveness of our methods. These figures position Pronokal Group as a leading company in the weight management sector.
truMED a bariatric care solution backed by science, powered by technology.
Improving long-term outcomes means reimagining the way services are delivered, reconnecting broken pathways and shifting to a more patient-centered approach to care. truMED supports this modern approach by providing real-time data and analysis to the care team while providing patients the tools they need to succeed.
truPRO is the doctor-facing component of the truMED solution – an application for healthcare professionals that powers digital interaction with patients through the truME mobile app. truPRO simplifies the work of keeping patients on track to meet their health gain goals by delivering real-time data about each patient’s diet, activity, mental health, and medical history from the truME mobile app to the care team, allowing them to monitor, triage, and care for patients remotely, and better support them at in-office visits.
truME the patient-facing mobile app works with truPRO and its connected weighing scale and wearable device to support behavioral, dietary, physical, and medical interventions designed to optimize long-term results for patients on their health gain journey.
Wisepress Medical Bookshop
15A London Rd
Maidstone
ME16 8LY
Phone: +44 20 8715 1812
bookshop@wisepress.com
www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.
Copyright © ECO 2024. All Rights Reserved | LookUs & Online Makale |
EASO & WOF selected Call4Posters™ as their preferred poster printing partner for the ECO-ICO 2023 Congress.
Call4Posters® Poster Printing Service is a poster service that will enable you to have your poster professionally printed, reviewed and shipped directly to the congress venue.
Your poster will be waiting for you at the helpdesk in the poster exhibition area – no need to worry about carrying it on the plane.
To start submitting your poster for printing, please visit
https://eu.call4posters.com/eco/c/1667?meetingposter=true